MAG and neuropathy: BTKi did not seem to improve renal function (Case 1), while bortezomib‐based regimens demonstrated a beneficial activity on the hematological and organ response, even when used as second‐line therapy after chemoimmunotherapy (Case 3) and also with coexistence of anti‐MAG neuropathy (Case 2).